Results 231 to 240 of about 366,991 (303)

α2,3‐Sialyltransferase (ST3Gal1) regulates endometrioid‐type epithelial ovarian cancer cell migration and invasion via VEGF‐R2/JAK2/STAT3 signaling cascades

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To investigate the role of ST3 β‐galactoside α‐2,3‐sialyltransferase 1 (ST3Gal1) and vascular endothelial growth factor receptor 2 (VEGF‐R2) in endometrioid‐type epithelial ovarian cancer (E‐OC) because aberrant α2,3‐sialylation mediated by ST3Gal1 and VEGF‐R2‐related angiogenesis is linked with tumor progression. Methods ST3Gal1 and
Wei‐Ting Chao, Chia‐Hao Liu, Szu‐Ting Yang, Chen‐Hao Lin, Liang‐Wei Wang, Peng‐Hui Wang   +5 more
wiley   +1 more source

Epigenetic Regulation in the Pathogenesis of Renal Inflammation: Insights and Therapeutic Potentials

iNew Medicine, EarlyView.
ABSTRACT Renal inflammation is a common pathological process in various kidney diseases, often initiated by factors such as toxins, ischemia, or autoimmune reactions. This inflammatory response can result in structural damage and a rapid decline in renal function.
Yu‐Hang Dong, Xiao‐Yu Shen, Han‐Cheng Jin, Xiang‐Yu Li, Hao He, Xiao‐Ming Meng   +5 more
wiley   +1 more source

Silymarin alleviates cisplatin-induced cachexia via modulating tripartite motif containing 63 (TRIM63) and myogenin.

Indian J Pharmacol
Das S, Jyotika, Pahuja R, Kushwaha S, Shrivastava R.   +4 more
europepmc   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

N6‐Methyladenosine (m6A) in Liver Disease: Pathogenic Mechanisms and Therapeutic Potential

iNew Medicine, EarlyView.
ABSTRACT Accumulating evidence highlights the critical role of epigenetic modifications, particularly N6‐methyladenosine (m6A), in liver disease. As the most abundant RNA modification in eukaryotic cells, m6A is dynamically regulated by multicomponent m6A methyltransferases (e.g., METTL3 and METTL14), demethylases (FTO and ALKBH5), and m6A‐binding ...
Yingfen Chen, Ru Ya, Ziling Zhang, Siyue Dong, Seol Hee Park, Wonhyo Seo, Yong He   +6 more
wiley   +1 more source

Baicalin attenuates cisplatin-induced cochlear hair cell damage by modulating the ROS-p38 MAPK signaling pathway. [PDF]

Front Cell Dev Biol
Zhang Q, Wang Y, Zhang C, Li S, Yin Q, Zhou C, Dong C, Bu C.   +7 more
europepmc   +1 more source

Engineered extracellular vesicles for precision renal therapy: Bioengineering strategies and clinical translation

Interdisciplinary Medicine, EarlyView.
Engineered extracellular vesicles (EVs) offer a versatile platform for kidney‐targeted therapy. This review summarizes bioengineering strategies, including cargo loading, surface modification, biomimetic fabrication, and biomaterial integration. We highlight translational challenges and propose future solutions to accelerate the clinical application of
Linru Shi, Bei Li, Wanzhu Liu, Haifeng Wu, Wenrong Xu, Cheng Ji, Hui Qian   +6 more
wiley   +1 more source

Eugenoplatin (a phyto-chemo drug conjugate) targets cancer stem cells through inhibition of the β-catenin signaling in triple-negative breast cancer cells. [PDF]

J Transl Med
Alraouji NN, Al-Otaibi B, Khan MY, Al-Mohanna F, Al-Mazrou A, Al-Tweigeri T, Al-Jammaz I, Alaiya AA, Cherkaoui M, Aboussekhra A.   +9 more
europepmc   +1 more source

Biodegradable folate-mediated chitosan-CQD nanocarriers for targeted and stimuli-responsive cisplatin delivery in melanoma. [PDF]

Nanoscale Adv
Srivastava SK, Yadav M, Singh P, Tripathi S, Verma AK, Parmar AS.   +5 more
europepmc   +1 more source

Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab. [PDF]

Oncol Ther
Di Lorenzo G, Di Maio M, Buonerba C.
europepmc   +1 more source